The reevaluation of the Hong Kong stock Technology sector reveals that the Innovative Drugs sector is also expected to迎迎迎 DeepSeeK moment.

① Hong Kong stocks in the Biomedical sector are strengthening in the short term, which Bullish factors are worth paying attention to? ② The number of new drugs under research in our country has jumped to second in the Global ranking, what new support does the policy provide?

cls.cn04:01 ET

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$18.36 From HK$17.95, Keeps at Neutral

MT Newswires03:28 ET · Ratings

The era of large models in medicine! AI empowers the Industry to press the "accelerator", while the industry still hopes for revolutionary technology to emerge | Medicine Bottoming Series ④

① AI, with its powerful data summarization capabilities, is driving further innovation in the Medical and pharmaceutical fields; ② however, pharmaceutical companies still feel troubled about how to leverage AI in research and development; ③ industry insiders believe that the limitations of technology and the inviolability of ethical and legal responsibilities objectively prevent AI from having the capability to be a responsible entity.

cls.cn02:44 ET

Nomura: Maintain HANSOH PHARMA (03692) "Neutral" rating, raise Target Price to HKD 18.36.

The bank indicated that the revenue forecast for HANSOH PHARMA for the fiscal years 2024 and 2025 is 0.4% and 2.1% higher than the market consensus expectations, while the profit forecast is 3% and 1% lower than the market consensus expectations.

Zhitong Finance02:23 ET

The enthusiasm for pharmaceutical companies going public in Hong Kong continues! Two leading COVID-19 drug companies are entering the market. How can they break the dilemma of single revenue sources?

In the past three months, nearly 20 pharmaceutical companies have submitted listing applications to the Hong Kong Stock Exchange, including True Biologics and Wangshan Wangshui, two former stars in the COVID-19 pharmaceutical industry; the primary revenue of these two companies is still concentrated on products related to COVID-19 authorization or commercialization, which has significantly declined, providing limited Cash / Money Market.

cls.cn20:43 ET

Hansoh Pharma's HS-20093 Receives Breakthrough Therapy Designation for Osteosarcoma

TipRanksFeb 25 06:09 ET